8-K: Henry Schein Exceeds Q4, Full-Year 2025 Earnings; Boosts 2026 Outlook

Henry Schein, Inc. reported strong fourth-quarter and full-year 2025 financial results, surpassing increased guidance and introducing optimistic 2026 financial projections.

Summary

• Fourth-quarter 2025 GAAP diluted EPS was $0.85, up from $0.74 in Q4 2024.
• Fourth-quarter 2025 non-GAAP diluted EPS was $1.34, an increase from $1.19 in Q4 2024.
• Total net sales for Q4 2025 reached $3.4 billion, marking a 7.7% increase over Q4 2024, driven by 4.9% internal sales growth.
• Full-year 2025 total net sales were $13.2 billion, a 4.0% increase compared to 2024.
• Full-year 2025 GAAP diluted EPS was $3.27, up from $3.05 in 2024.
• Full-year 2025 non-GAAP diluted EPS was $4.97, compared to $4.74 in 2024.
• The company repurchased approximately 2.8 million shares for $200 million in Q4 2025, and 12.1 million shares for $850 million in full-year 2025.
• Henry Schein introduced 2026 non-GAAP diluted EPS guidance in the range of $5.23 to $5.37.
• Total sales growth for 2026 is expected to be approximately 3% to 5% over 2025.
• Adjusted EBITDA for 2026 is projected to grow mid-single digits compared with 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance exceeding prior guidance, robust sales growth across key segments, and optimistic 2026 financial guidance, further bolstered by significant share repurchases and a planned CEO transition.

Positives

• Q4 2025 sales growth was the highest in 15 quarters, reflecting strong momentum across all businesses.
• Fourth-quarter earnings exceeded the increased 2025 financial guidance provided in the third quarter.
• Global Dental Distribution equipment sales showed strong growth, particularly in the U.S., Germany, Brazil, Canada, and Australia, increasing 12.2% (9.1% in constant currencies).
• Global Specialty Products sales increased significantly by 14.6% (11.1% in constant currencies), driven by dental implant and endodontics sales.
• Global Technology sales grew 8.4% (7.6% in constant currencies) due to accelerated adoption of cloud-based software and new solutions.
• The company's 2025-2027 BOLD+1 strategic plan is demonstrating effective execution, positioning the company well for future growth.
• A new CEO, Fred Lowery, is joining next week, signaling a leadership transition aimed at continued success.
• The company has $780 million authorized and available for future stock repurchases, indicating ongoing commitment to shareholder returns.

Negatives

• Global Medical Distribution experienced softness in the respiratory product category during Q4 2025.
• The company is unable to provide a reconciliation of its 2026 non-GAAP diluted EPS guidance to GAAP diluted EPS without unreasonable effort, citing uncertainty regarding restructuring expenses and other costs.

Risks

• Dependence on third parties for the manufacture, supply of products, raw materials, and purchased components.
• Risks related to achieving strategic growth objectives, including anticipated results of restructuring and value creation initiatives.
• Risks associated with the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025.
• Challenges associated with transitions in senior company leadership.
• Ability to develop or acquire and maintain and protect new products and services, particularly technology and specialty products, and utilize new technologies that achieve market acceptance with acceptable margins.
• Transitional challenges associated with acquisitions and joint ventures, including failure to achieve anticipated synergies/benefits and significant demands on operational and financial functions.
• Certain provisions in governing documents that may discourage third-party acquisitions.
• Adverse changes in supplier rebates or other purchasing incentives.
• Risks related to the sale of corporate brand products.
• Risks related to activist investors.
• Security risks associated with information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident).
• Effects of a highly competitive and consolidating market, including competition from third-party online commerce sites.
• Political, economic, and regulatory influences on the health care industry.
• Risks from expansion of customer purchasing power and multi-tiered costing structures.
• Increases in shipping costs for products or other service issues with third-party shippers, and increases in fuel and energy costs.
• Changes in laws and policies governing manufacturing, development, and investment in territories and countries where business is conducted.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment, consumer confidence, sovereign debt levels, fluctuations in energy pricing, and the value of the U.S. dollar.
• Failure to comply with existing and future regulatory requirements, including those relating to health care, the EU Medical Device Regulation, health care fraud, and data privacy.
• Changes in tax legislation, tax rates, and availability of certain tax deductions.
• Risks related to product liability, intellectual property, and other claims.
• Risks associated with customs policies or legislative import restrictions.
• Risks associated with disease outbreaks, epidemics, pandemics (such as COVID-19), or similar widespread public health concerns and other natural or man-made disasters.
• Risks associated with global operations.
• The threat or outbreak of war (e.g., Ukraine, Israel-Gaza), terrorism, or public unrest.
• Changes to laws and policies governing foreign trade, tariffs, and sanctions or greater restrictions on imports and exports.
• Supply chain disruption.
• Litigation risks, new or unanticipated litigation developments, and the status of litigation matters.
• Dependence on senior management (including the transition to a new Chief Executive Officer), employee hiring and retention, increases in labor costs or health care costs, and relationships with customers, suppliers, and manufacturers.
• Disruptions in financial markets.

Future Outlook

Henry Schein expects 2026 non-GAAP diluted EPS to be in the range of $5.23 to $5.37, with total sales growth projected between 3% and 5% over 2025. Adjusted EBITDA is anticipated to grow mid-single digits. This guidance assumes consistent foreign currency exchange rates and excludes certain non-GAAP adjustments like restructuring costs and amortization of acquired intangible assets, which the company cannot reconcile to GAAP without unreasonable effort.

Management Comments

• "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particularly our global equipment, specialty products and technology businesses. This drove our strong fourth-quarter earnings which exceeded the increased 2025 financial guidance we provided in our third quarter earnings release."
• "The growth we have achieved, especially over the second half of 2025, demonstrates the effective execution of our 2025-2027 BOLD+1 strategic plan, and positions us well for the future. Our 2026 financial guidance underscores sustained growth through continued strong execution of these strategies."
• "I am excited that Fred Lowery will join Henry Schein as our CEO next week and believe that he will lead Henry Schein to even greater success."

Industry Context

StockSavvy.ai notes that Henry Schein's strong performance in global equipment, specialty products, and technology businesses aligns with broader trends in the healthcare industry, where practitioners are increasingly investing in advanced solutions and digital technologies to enhance operational efficiency and clinical outcomes. The acceleration in cloud-based software adoption and new solution launches reflects the ongoing digital transformation within dental and medical practices. The slight softness in the respiratory product category for medical distribution could indicate a normalization or shift in demand post-pandemic, but overall growth in medical products suggests underlying resilience in the sector.

Management Changes

Legal Proceedings

• Litigation settlements were recorded as non-GAAP adjustments in Q4 2025 and YTD 2025, including for opioid-related lawsuits.
• Litigation settlements related to the October 2023 cyber incident and opioid-related lawsuits were recorded in YTD 2024.

Stakeholder Impact

• Shareholders benefit from strong financial performance, increased diluted EPS, and significant share repurchases ($850 million in 2025).
• Customers are positively impacted by the company's continued investment in technology and specialty products, leading to new solutions and improved operational success for healthcare professionals.
• Employees (Team Schein Members) are part of a growing company with strategic plans for future success, though leadership transitions and restructuring initiatives may bring changes.

Next Steps

• Fred Lowery will join Henry Schein as CEO next week (following February 24, 2026).

Key Dates

Recommendation

The company delivered strong financial results for Q4 and full-year 2025, exceeding its own increased guidance. The 2026 financial outlook is positive, projecting continued growth in sales and earnings. Significant share repurchases demonstrate a commitment to shareholder value. The upcoming CEO transition, while a change, is framed positively by current management. These factors collectively suggest a favorable investment opportunity.

Keywords

Henry Schein, HSIC, Financial Results, Earnings, Healthcare Solutions, Dental, Medical, Distribution, Specialty Products, Technology, EPS, Sales Growth, Guidance, Stock Repurchase, CEO Transition, SEC Filing